Biotech Startups

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.

5 investors

Amplified Sciences is a clinical-stage diagnostics company that has developed an ultra-sensitive optical reporter platform for multi-omics diagnostic tests, aimed at helping clinicians detect, treat, and monitor difficult diseases. Its diagnostics support earlier and more accurate detection, including tests for patients at higher risk of pancreatic cancer.

5 investors

AMPLY Discovery is a UK-based biotech company that uses AI and computational biology to identify therapeutic targets in non-coding regions of the genome and develop first-in-class drugs through an integrated discovery platform combining machine learning with wet-lab validation. The company is developing therapeutics for oncology and drug-resistant infectious diseases, particularly antimicrobial-peptide and long non-coding RNA oligonucleotide programmes.

5 investors

AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development. The company was founded on breakthrough research from Karolinska Institutet targeting improved heart muscle contractility through a differentiated mechanism.

5 investors

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

5 investors

Animab develops proprietary antibodies that mimic natural intestinal protection mechanisms to safeguard piglets' health during post-weaning, a critical period in livestock production. The company's biologically-derived solutions target specific intestinal pathogens without disrupting the healthy microbiome.

5 investors

Anja Health provides cord blood banking and stem cell storage services from umbilical cords and placentas for families. The company aims to make stem cell preservation accessible and affordable for new parents.

5 investors

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.

5 investors

AOI Biosciences is a Japanese biotech company focused on infectious diseases and autoimmune disorders, combining data analysis technology with proprietary bio-technology. It operates diagnostic testing, drug discovery, and drug discovery support businesses.

5 investors

Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.

5 investors

Apreo Health develops a bronchoscopic treatment for severe emphysema using a self-expanding airway scaffold designed to reduce trapped air and improve lung function. The company targets patients with severe emphysema who have limited treatment options.

5 investors

5 investors

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.

5 investors

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches. The company is developing a portfolio of DNA editing technologies capable of targeting over 90% of the human genome for therapeutic applications.

5 investors

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

5 investors

Arsenale builds an end-to-end biomanufacturing platform that combines micro-scale bioreactors, AI software, and large-scale fermentation infrastructure for precision fermentation at industrial scale. The system spans organism design in the lab to industrial production, targeting bio-based production of food, materials, and goods.

5 investors

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.

5 investors

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).

5 investors

Atelerix develops patented alginate hydrogel technology that stabilises cells, tissues, blood products, viruses and vectors at room temperature, removing the need for cryopreservation and cold-chain shipping. Spun out of Newcastle University, it serves researchers, biotech firms and diagnostics teams needing to store and transport biological samples.

5 investors

A biotechnology company developing new therapies for patients with high unmet medical needs.

5 investors

Atrandi makes Flux, a device that isolates thousands to hundreds of thousands of individual cells simultaneously into semi-permeable capsules for downstream genomic and microbial analysis. The system is designed for life science research and can operate in field settings or laboratory environments.

5 investors

5 investors

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders. The company targets both rare and prevalent brain diseases, using biomarker-driven development strategies to demonstrate on-target activity early in clinical trials.

5 investors

PBM Capital is an investment firm that provides funding and operational support to scientists and entrepreneurs, helping them bring products to market and grow their businesses. Its portfolio focuses on companies developing therapies in the life sciences and healthcare space.

5 investors